RLYBRallybio Corpvs its industry peers
A metric-by-metric comparison of Rallybio Corp against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RLYBEsta | $89M#8 | 3.4x#2 | 0.9x#2 | 104.0x#4 | 34.9%#2 | 84.5%#1 | -3853.6%#4 | -9.5%#2 | — | — | 265.6%#1 | — |
| GNLX | $114M#1 | — | 7.1x#11 | 14308.8x#9 | 0.0%#5 | -7.6%#9 | -415175.0%#8 | -199.5%#12 | -424.2%#2 | — | -35.5%#9 | — |
| MIST | $114M#2 | — | 6.3x#9 | — | — | -51.9%#13 | — | -0.3%#1 | — | — | -52.7%#11 | — |
| COYA | $111M#3 | — | 2.6x#5 | 14.0x#3 | 123.6%#1 | -42.6%#12 | -283.9%#3 | -49.0%#4 | — | — | -12.2%#5 | — |
| CPIX | $106M#4 | — | 6.1x#8 | 2.4x#1 | 17.6%#3 | 56.2%#3 | -6.3%#2 | -16.3%#3 | — | — | 114.5%#2 | — |
| PLYX | $101M#5 | — | 9.3x#12 | — | — | 70.4%#2 | — | -82.1%#7 | — | — | — | — |
| CTOR | $96M#6 | — | 2.4x#4 | — | — | -17.1%#11 | — | -61.3%#5 | — | — | -43.0%#10 | — |
| ANIX | $95M#7 | — | 6.6x#10 | 454.4x#6 | 0.0%#5 | 13.0%#6 | -5571.9%#6 | -75.5%#6 | -87.0%#1 | — | -18.5%#7 | — |
| NTHI | $87M#9 | — | — | 2185.7x#7 | -51.8%#9 | -422.3%#16 | -145637.5%#7 | — | — | — | -68.2%#12 | — |
| EMMA | $84M#10 | — | — | 6.8x#2 | -25.2%#7 | -16.1%#10 | 1.9%#1 | — | — | 4#2 | — | — |
| ALDX | $84M#11 | — | 2.2x#3 | — | — | 39.4%#4 | — | -89.3%#8 | — | — | -71.5%#13 | — |
| OSTX | $84M#12 | — | — | — | — | -223.7%#15 | — | — | — | — | -16.5%#6 | — |
| MAIA | $84M#13 | — | 4.1x#7 | — | — | 3.7%#7 | — | -108.3%#10 | — | — | -11.8%#4 | — |
| LNAI | $84M#14 | 1.1x#1 | — | 2557.0x#8 | -47.8%#8 | -101.3%#14 | -576678.5%#9 | — | — | 5#1 | -83.0%#14 | — |
| ACET | $84M#15 | — | 0.7x#1 | — | — | 0.3%#8 | — | -97.2%#9 | — | — | -26.5%#8 | — |
| YARW | $83M#16 | 3.7x#3 | 3.8x#6 | 146.4x#5 | 13.8%#4 | 33.5%#5 | -5219.1%#5 | -120.0%#11 | — | — | 107.4%#3 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-18.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice